Pulmonary Hypertension Associated with HIV Infection

Southern Medical Journal

Volumn 94, Issue 6, 2001, Pages 635-639

  Seoane, Leonardo ^a,b   Shellito, Judd ^a   Welsh, David ^a   DeBoisblanc, Bennet P ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; RISK FACTORS;

EID: 0035381044     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200106000-00018     Document Type: Article

References (49)

1. Mitchell DM, Miller RF: AIDS and the lung: new developments in pulmonary diseases affecting HIV infected individuals. Thorax 1995; 50:294-302
2. Meduri GU, Stein DS: Pulmonary manifestations of acquired immunodeficiency syndrome. Clin Infect Dis 1992; 14:98-113
3. Kim KK, Factor SM: Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987; 18:1293-1296
4. Goldsmith GH Jr, Baily RG, Brettler DB, et al: Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med 1988; 108:797-799
5. Mani A, Smith GJ: HIV and pulmonary hypertension: a review. South Med J 1994; 87:357-362
6. Coplan NL, Shimony RY, Iochim HL, et al: Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med 1990; 89:96-99
7. Polos PG, Wolf D, Harley RA, et al: Primary pulmonary hypertension and human immunodeficiency virus infection: two reports and a review of the literature. Chest 1992; 101:474-478
8. Tomashefski JF Jr, Hirsch CS: The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 1980; 11:133-145
9. Arnett EN, Battle WE, Russo JV, et al: Intravenous injection of talc-containing drugs intended for oral use: a cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 1976; 60:711-718
10. Mesa RA, Edell ES, Dunn WF, et al: Subspecialty clinics: human immunodefiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73:37-45
11. McDonnell PJ, Toye PA, Hutchins GM: Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127:437-441
12. Hadengue A, Benhamon MK, Lebrec D, et al: Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520-528
13. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117
14. Himelmann RB, Dohrmann M, Goodmann P, et al: Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989; 64:1396-1399
15. Speich R, Jenni R, Opravil M, et al: Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268-1271
16. Mehta NJ, Ijaz KA, Rajal N, et al: HIV-related pulmonary hypertension analytic review of 131 cases. Chest 2000; 118:1133-1141
17. Golpe R, Fernandez-Infante B, Fernandez-Rozas S: Primary pulmonary hypertension associated with human immunodeficiency virus infection. Postgrad Med J 1998; 74:400-404
18. Petitpretz P, Brenot F, Azarian R, et al: Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994; 89:2722-2727
19. Opravil M, Pechere M, Speich R, et al: HIV-associated primary pulmonary, a case control study. Am J Respir Crit Care Med 1997; 155:990-995
20. Rubin LJ: Primary pulmonary hypertension. Chest 1993; 104:236-250
21. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 155:343-349
22. Pietre GG: Histopathology of primary pulmonary hypertension: Chest 1994; 105(suppl 2):2s-6s
23. Rich S, Brundage B: Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cardiol 1989; 14:545-550
24. Rubin LJ: Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995; 75:51A-54A
25. Rich S: Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest 1998; 114:237S-241S
26. Voelker NF, Tuder RM: Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8:2129-2138
27. Cool CD, Kennedy D, Voelkel NF, et al: Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28:434-442
28. Cool CD, Stewart JS, Werahera P, et al: Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Am J Pathol 1999; 155:411-419
29. Mette SA, Palevsky HI, Pietra GG, et al: Primary pulmonary hypertension in association with HIV infection, a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145:1196-2000
30. Tuder RM, Weinberg A, Bates TO, et al: Tat-protein of HIV enhances inflammatory cell binding and PDGF levels in CMV infected endothelial cells (Abstract). Circulation 1994; 90:I-417
31. Ehrenreich H, Rieckmann P, Sinowatz F, et al: Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993; 150:4601-4609
32. Hofmann FM, Wright AD, Dohadwala MM, et al: Exogenous tat protein activates endothelial cells. Blood 1993; 82:2774-2780
33. Humbert M, Monti G, Fartoukh M, et al: Platelet derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11:554-559
34. Chalifoux LV, Simon MA, Pauley DR, et al: Arteriopathy in macaques infected with simian immunodeficiency virus. Lab Invest 1992; 67:338-349
35. Gillespie MN, Hartsfield CL, O'Conner WN, et al: Pulmonary hypertension in a murine model of AIDS. Am J Respir Crit Care Med 1994; 150:194-199
36. Morse JH, Barst RJ, Itescu S, et al: Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996; 153:1299-1301
37. Morse JH, Jones AC, Barst RJ, et al: Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95:2603-2606
38. Nichols WC, Koller DL, Slovis B, et al: Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277-280
39. Deng Z, Haghighi F, Helleby L, et al: Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Resp Crit Care Med 2000; 161:1055-1059
40. Deng Z, Morse JH, Slager SL, et al: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737-744
41. Machado RD, Pauciulo MW, Thompson JR, et al: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68:92-102
42. Pellicelli AM, Palmieri F, D'Ambrosio C, et al: Role of human immunodeficiency virus in primary pulmonary hypertension - case reports. Angiology 1998; 49:1005-1011
43. Rich S, Kaufmann E, Levy PS: The effect of high dose calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
44. Louis M, Thorens JB, Chevrolet JC: Calcium channel blockers, testing for primary pulmonary hypertension associated with HIV infection (Abstract). Am Rev Respir Dis 1993; 147:536A
45. Shapiro SM, Oudiz RJ, Cao T, et al: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343-349
46. Barst RJ, Rubin LJ, McGoon MD, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
47. Stricker H, Domenighetti G, Mombelli G: Prostacyclin for HIV-associated pulmonary hypertension (Letter). Ann Intern Med 1997; 127:1043
48. McAllister RG, Crow JW, Wade M, et al: International multicenter double blind randomized parallel placebo controlled comparison of the safety and effects of chronic subcutaneous UT-15 plus conventional therapy to conventional therapy in patients with primary pulmonary hypertension. Research Triangle Park, NC, United Therapeutics Corp, 1999
49. Roux S: Double blind randomized placebo controlled study to assess the effects of Ro 47-0203 (Bosentan) on exercise capacity in patients with pulmonary artery hypertension. Voorhees, NJ, Hesperion USA, 2000